Zuellig Pharma, a leading healthcare services provider, is headquartered in Singapore and operates extensively across Asia. Founded in 1922, the company has established itself as a key player in the pharmaceutical distribution and healthcare solutions industry, serving markets in over 13 countries, including China, Malaysia, and the Philippines. Specialising in supply chain management, logistics, and market access services, Zuellig Pharma is renowned for its innovative approach to healthcare delivery. The company’s unique offerings include advanced temperature-controlled logistics and digital health solutions, which enhance patient access to essential medicines. With a strong market position, Zuellig Pharma has achieved numerous milestones, including partnerships with major pharmaceutical companies and recognition for its commitment to improving healthcare outcomes in the region. Its dedication to quality and efficiency continues to set it apart in the competitive landscape of healthcare services.
How does Zuellig Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zuellig Pharma's score of 32 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Zuellig Pharma reported total carbon emissions of approximately 285,822,000 kg CO2e. This figure includes 10,640,000 kg CO2e from Scope 1 emissions, 64,587,000 kg CO2e from Scope 2 emissions, and 247,499,000 kg CO2e from Scope 3 emissions. Notably, the company has made significant strides in reducing its carbon footprint, achieving a reduction from 451,111,000 kg CO2e in 2021 to the current figure. Zuellig Pharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions, specifically from fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations, also by 2030. These targets align with industry standards and reflect Zuellig Pharma's commitment to sustainable practices within the healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 9,551,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 51,255,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 341,689,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zuellig Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.